FOR FURTHER INFORMATION CONTACT: Evelyn Bohor, at *ero@usccr.gov* or by phone at 202–376–7533.

SUPPLEMENTARY INFORMATION: Interested members of the public may listen to the discussion by calling the following toll-free conference call-in number: 1–800–667–5617 and conference call 7737084. Please be advised that before placing them into the conference call, the conference call operator will ask callers to provide their names, their organizational affiliations (if any), and email addresses (so that callers may be notified of future meetings). Callers can expect to incur charges for calls they initiate over wireless lines, and the Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over land-line connections to the toll-free conference call-in number.

Persons with hearing impairments may also follow the discussion by first calling the Federal Relay Service at 1–800–877–8339 and providing the operator with the toll-free conference call-in number: 1–800–667–5617 and conference call 7737084.

Members of the public are invited to make statements during the open comment period of the meeting or submit written comments. The comments must be received in the regional office approximately 30 days after each scheduled meeting. Written comments may be mailed to the Eastern Regional Office, U.S. Commission on Civil Rights, 1331 Pennsylvania Avenue, Suite 1150, Washington, DC 20425, faxed to (202) 376–7548, or emailed to Evelyn Bohor at *ero@usccr.gov.* Persons who desire additional information may contact the Eastern Regional Office at (202) 376–7533.

Records and documents discussed during the meeting will be available for public viewing as they become available at *https://www.facadatabase.gov/FACA/FACAPublicViewCommitteeDetails?id=a10t0000001gzlXAAQ;* click the ''Meeting Details'' and ''Documents'' links. Records generated from this meeting may also be inspected and reproduced at the Eastern Regional Office, as they become available, both before and after the meetings. Persons interested in the work of this advisory committee are advised to go to the Commission's website, *www.usccr.gov,* or to contact the Eastern Regional Office at the above phone numbers, email or street address.

Agenda

February 28, 2019, Thursday; 3:00 p.m. (EST)

- Roll Call
- Project Planning
- Open Comment
- Adjourn

Dated: February 21, 2019.

David Mussatt,

Supervisory Chief, Regional Programs Unit.

[FR Doc. 2019–03281 Filed 2–25–19; 8:45 am]

BILLING CODE P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B–05–2019]

Foreign-Trade Zone (FTZ) 93—Raleigh/Durham, North Carolina, Notification of Proposed Production Activity, GlaxoSmithKline, PLC (Pharmaceutical Products), Zebulon, North Carolina

The Triangle J Council of Governments, grantee of FTZ 93, submitted a notification of proposed production activity to the FTZ Board on behalf of GlaxoSmithKline, PLC (GlaxoSmithKline), located in Zebulon, North Carolina. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on February 13, 2019.

GlaxoSmithKline already has authority to produce certain pharmaceutical products within Site 6 of FTZ 93. The current request would add finished products and a foreign-status material/component to the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited to the specific foreign-status material/component (dolutegravir sodium) and specific finished products described in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt GlaxoSmithKline from customs duty payments on the foreign-status material/component used in export production. On its domestic sales, for foreign-status dolutegravir sodium (duty rate, 6.5%) and foreign-status components in the existing scope of authority, GlaxoSmithKline would be able to choose the duty-free rate during customs entry procedures that applies to: Dolutegravir sodium/rilpivirine HCl; Juluca tablets® (anti-viral); dolutegravir sodium tablets (anti-viral); Tivicay tablets® (anti-viral); abacavir sulfate/dolutegravir sodium/lamivudine tablets (anti-viral); Triumeq tablets® (anti-viral); dolutegravir/lamivudine tablets (anti-viral); Dovato tablets® (anti-viral); umeclidinium bromide/vilanterol trifenatate ellipta (respiratory inhaler); Anoro Ellipta® (respiratory inhaler); umeclidinium bromide ellipta (respiratory inhaler); Incruse Ellipta® (respiratory inhaler); fluticasone furoate/umeclidinium bromide/vilanterol trifenatate ellipta (respiratory inhaler); and, Trelegy Ellipta® (respiratory inhaler). GlaxoSmithKline would be able to avoid duty on foreign-status components which become scrap/waste. Customs duties also could possibly be deferred or reduced on foreign-status production equipment.

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary at the address below. The closing period for their receipt is April 8, 2019.

A copy of the notification will be available for public inspection at the Office of the Executive Secretary, Foreign-Trade Zones Board, Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230–0002, and in the ''Reading Room'' section of the Board's website, which is accessible via *www.trade.gov/ftz.*

For further information, contact Diane Finver at *Diane.Finver@trade.gov* or (202) 482–1367.

Dated: February 19, 2019.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2019–03236 Filed 2–25–19; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B–57–2018]

Foreign-Trade Zone (FTZ) 149—Freeport, Texas, Authorization of Production Activity, DSM Nutritional Products, LLC (Vinylol), Freeport, Texas

On September 11, 2018, the Port of Freeport, grantee of FTZ 149, submitted a notification of proposed production activity to the FTZ Board on behalf of DSM Nutritional Products, LLC, within Subzone 149B, in Freeport, Texas.

The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the **Federal Register** inviting public comment (83 FR 47131, September 18, 2018). On February 19, 2019, the applicant was notified of the FTZ Board's decision that no further